Company intelligence / Profile preview

TcL Pharma

Nantes, France

Ownership: Private
Development stage: Other

Overview

TcL Pharma was a French biotechnology company specializing in the development of innovative immunotherapies for organ transplantation and autoimmune diseases. The company's core technology focused on the CD28/B7 molecular pathway to induce immune tolerance without the need for long-term immunosuppression. Its lead candidate, FR104, is a pegylated monoclonal antibody fragment (Fab') designed to selectively block CD28. TcL Pharma merged with Effimune in 2013, which subsequently merged with OSE Pharma in 2016 to form OSE Immunotherapeutics. The company's legacy continues through the ongoing development of its CD28 antagonist programs within OSE Immunotherapeutics.

Therapeutic areas: Immunology
Modalities: Monoclonal antibody fragmentAntibody
Industry: Biotech

Partnerships

Janssen Biotech

Beyond the preview

Go deeper on TcL Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TcL Pharma.

Explore the full profile